Novosound, a Scottish Sensor Technology Startup Targets Expansion in APAC

On the back of recent client wins with global energy giants in the Middle East and North America, Scottish sensor technology scale-up company Novosound is targeting expansion in the APAC region.

Novosound’s Ceilidh system, a wide area corrosion monitoring system for industrial groups seeking to improve the efficiency and safety of their assets, will be featured at the 20th World Conference for Non-Destructive Testing (WCNDT) in Incheon, South Korea between 27th-30th May, hosted by the Korean Society for Nondestructive Testing (KSNT).

The Ceilidh is a fully patented system for the monitoring of corrosion and solves a number of industry challenges including corrosion under composite-wraps. Novosound’s recent commercial wins in the international industrial sector follow previous contract wins with Atom Group (Greece), Uniper (UK), BAE Systems (UK), and GE Aviation (USA).

Novosound CEO and Founder Dave Hughes said:

“The Ceilidh system represents a significant breakthrough in the field of non-destructive testing, addressing complex challenges and specifically tailored for industries where corrosion monitoring is absolutely critical.”

CEO Dave Hughes will also be meeting some of South Korea’s most high profile technology and electronics groups during the company’s visit to showcase its wireless wearable ultrasound system, the Slanj. The Slanj platform is currently being trialled with USA and European digital healthcare partners, utilising a pioneering technology which is able to look deeper into the body and enhance the monitoring of biometrics like blood pressure and dehydration compared to optical, magnetic, and electrical sensors.

Dave Hughes added: “We look forward to exploring potential collaborations across the industrial and digital health sectors during our forthcoming visit to South Korea, as we proudly carry the banner for Scottish innovation and its world-class capabilities.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”